Enzo Biochem

356 articles about Enzo Biochem

• Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates

  3/15/2021

  Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemic Second quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-year

• Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Company will present at H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10, 2021.

• Enzo Announces its GENFLEX™ Molecular Test Detects Current COVID-19 Variants

  3/2/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced results of an analysis showing that tests processed on the Company’s proprietary GENFLEX™ molecular diagnostic platform are successfully able to detect the presence of currently known variants of COVID-19. 

• Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15Conference Call and Webcast Scheduled for March 15, 2021, 4:30 pm ET

  3/1/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that it will report second quarter 2021 financial results on Monday, March 15, 2021, after the market close

• Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

  2/3/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of Sclerostin”

• ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES

  1/20/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Enzo Board of Directors has formed two new committees to support strategy related to targeting and execution of new business opportunities and development and support for new members of the leadership team within the Company. The establishment of the new board committees follows Enzo’s recent announcement of quarterly o

• ENZO BIOCHEM TO PARTICIPATE IN THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT

  1/5/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, today announced that it will participate in the 10 th  Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021 in concurrence with J.P. Morgan’s 39 th Annual Healthcare Conference. Barry Weiner, President, and David Bench, Chief Financial Officer, will host virtual 1x1 meetings during both sessions of the event as well as

• ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY’S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

  1/4/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has received an expansion of its Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) authorizing the use of pooled samples containing up to five individual swab specimens with the Company’s AMPIPROBE® SARS-Cov-2 Test System utilizing tests

• ENZO RESPONDS AFTER REVIEWING THE POSITION OF INSTITUTIONAL SHAREHOLDER SERVICES

  12/28/2020

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position of Institutional Shareholder Services (“ISS”) regarding the Company's executive compensation approach for the fiscal year ended July 31, 2020. To acknowledge and address the issues within the ISS report, Dr. Elazar Rabbani, the Company’s Chairperson and CEO, has requested the Compensation Commit

• Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment

  12/15/2020

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it will host a key opinion leader (KOL) webinar discussing the use of the GENFLEX™ Molecular System for COVID-19 testing and the role of testing in a post-vaccine treatment environment, on Thursday, December 17, 2020 at 12:00pm Eastern Time. Infectious disease specialists Bruce Hanna, PhD, NYU Grossman Sch

• Enzo Biochem Reports First Quarter Fiscal 2021 Financial Results and Provides Business Update

  12/9/2020

  Company reports $28.7 million in revenue,exceeding revenue guidance by $1.7 million and representing a 47% increase over sequential quarter and continued recovery and opportunity from impact of COVID-19 pandemic on business operations.

• ENZO BIOCHEM ANNOUNCES APPOINTMENT OF IAN B. WALTERS, MD, TO ITS BOARD OF DIRECTORS

  11/25/2020

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD, has been appointed to the Company’s Board of Directors effective immediately.   

• ENZO BIOCHEM ANNOUNCES APPOINTMENT OF MARY TAGLIAFERRI, MD, TO ITS BOARD OF DIRECTORS

  11/18/2020

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, MD, has been appointed to the company’s Board of Directors effective immediately.    “In 2020, Enzo reported significant progress in advancing our business plan to achieve profitability including strong results in many areas of our operations that position us for new levels of growth and momentum in 2021

• ENZO PROVIDES CORPORATE BUSINESS UPDATE

  11/17/2020

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that the company estimates revenue to meet or exceed $27 million, representing sequential growth of at least 40%, for the quarter ended October 31, 2020.   Enzo Biochem, Inc. also announced today that Fabian Blank and Peter Clemens have resigned from the company board of directors, effective immediately. Both board members were

• ENZO LAUNCHES PORTABLE MICROPLATE READER FOR USE WITH ITS ELISA AND ASSAY KITS TO SIMPLIFY LABORATORY WORKFLOW

  11/5/2020

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today the commercial launch of a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new opportunities in point-of-care medicine.

• ENZO BIOCHEM LAUNCHES GOTESTMENOW™ ONLINE PLATFORM FOR CONSUMERS TO DIRECTLY ORDER COVID-19 LABORATORY TESTS

  10/27/2020

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it has launched GoTestMeNow™, a new online platform that enables consumers to directly order physician-authorized laboratory testing.  

• 

  Biopharma Update on the Novel Coronavirus: October 27

  10/27/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.

• Enzo Biochem Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  10/13/2020

  Company reports $19.5 million in revenue and EPS of ($0.07) in the fourth quarter with significant margin expansion supported by rapid response to COVID-19 market opportunities Q1 21 first two months’ revenue reflect continued positive trend Conference call and live webcast scheduled for today, Tuesday, October 13, 2020 at 4:30 pm (ET)

• Enzo Biochem to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, October 13

  10/6/2020

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter and fiscal year 2020 financial results on Tuesday, October 13, 2020, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time. Tuesday, October 13 th @ 4:30pm ET Domestic

• 

  Biopharma Update on the Novel Coronavirus: September 9

  9/9/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.